Kisqali (ribociclib) is approved for certain types of early breast cancer. It is used in combination with endocrine therapy for patients with hormone receptor-positive, HER2-negative, lymph node-positive disease who are at high risk of recurrence [1][2].
When is Kisqali Recommended for Early Breast Cancer?
Kisqali is recommended as adjuvant treatment for patients with early-stage hormone receptor-positive, HER2-negative breast cancer that is lymph node-positive and at high risk of recurrence [1][2]. High risk is typically defined by certain tumor characteristics, such as size or grade, and a high recurrence score [3]. The combination therapy aims to reduce the risk of the cancer returning [4].
How Does Kisqali Work in Early Breast Cancer?
Kisqali is a cyclin-dependent kinase (CDK) inhibitor, specifically targeting CDK4 and CDK6 [5]. These kinases play a role in cell cycle progression, and their overactivity can drive the growth of cancer cells [5][6]. By inhibiting CDK4 and CDK6, Kisqali helps to slow down or stop the proliferation of cancer cells [5]. When used in early breast cancer, it is administered alongside endocrine therapy, such as an aromatase inhibitor or tamoxifen, which further targets hormone-driven tumor growth [1][2].
What Clinical Trials Support Kisqali's Use in Early Breast Cancer?
The approval of Kisqali for early breast cancer is based on the results of the monarchE trial [1][2]. This study demonstrated a statistically significant improvement in invasive disease-free survival in patients treated with Kisqali plus endocrine therapy compared to endocrine therapy alone [4][7].
What Are the Potential Side Effects of Kisqali?
Common side effects associated with Kisqali treatment include neutropenia (low white blood cell count), nausea, fatigue, diarrhea, vomiting, hair loss, and liver enzyme elevations [1][8]. Neutropenia is a particularly important side effect that requires regular monitoring [1][9]. Healthcare providers closely monitor patients for these and other adverse events throughout treatment [9].
What Is the Dosage and Administration of Kisqali?
The standard dose of Kisqali for early breast cancer is 600 mg taken orally once daily for 21 days, followed by 7 days off (a 28-day cycle) [1]. It is typically given in combination with endocrine therapy [1][2]. Dosage adjustments may be necessary based on tolerability and specific side effects [1].
When Does Kisqali's Patent Protection End?
Information on the patent expiry for Kisqali can be found on DrugPatentWatch.com [10]. Patent expiries are critical for the potential introduction of generic or biosimilar versions of the drug, which can impact pricing and accessibility [10].
How Does Kisqali Compare to Other Treatments for Early Breast Cancer?
In the adjuvant setting for hormone receptor-positive, HER2-negative early breast cancer, Kisqali is used in conjunction with endocrine therapy for high-risk patients [1][2]. Other treatment strategies for early breast cancer may include surgery, radiation therapy, chemotherapy, and targeted therapies depending on the specific characteristics and stage of the cancer [11]. The decision to use Kisqali is based on individual patient factors and risk assessment for recurrence [3][4].